EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)

Chiara Ciccarese iD, Thomas Büttner, Linda Cerbone, Ilaria Zampiva, Fernando Sabino M Monteiro, Umberto Basso, Martin Pichler, Maria Giuseppa Vitale, Ondrej Fiala, Giandomenico Roviello, Ray Manneh Kopp, Francesco Carrozza und 23 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.35141 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Chiara Ciccarese und 34 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First‐line immunotherapy (IO)‐based combinations have improved the outcome of clear cell RCC patients, including that of sRCC. Real‐world data confirming the adequate first‐line management of sRCC is largely lacking. We investigated the clinical features and the outcome of sRCC patients treated with IO‐based combinations within the ARON‐1 study population (NCT05287464). The primary objective was to define the incidence and baseline clinical characteristics of sRCC compared with non‐sRCC patients. The secondary objective was to describe the outcome of sRCC patients based on type of first‐line treatment (IO + IO vs. IO + tyrosin kinase inhibitor [TKI]). We identified 1362 mRCC patients with IMDC intermediate or poor risk, 226 sRCC and 1136 non‐sRCC. These two subgroups did not differ in terms of baseline characteristics. The median overall survival (OS) was 26.8 months (95%CI 21.6–44.2) in sRCC and 35.3 months (95%CI 30.2–40.4) in non‐sRCC patients ( p = .013). The median progression‐free survival (PFS) was longer in non‐sRCC patients compared to sRCC (14.5 vs. 12.3 months, p = .064). In patients treated with first‐line IO + TKI the median OS was 34.4 months compared to 26.4 months of those who received IO + IO ( p = .729). The median PFS was 12.4 months with IO + TKI and 12.3 months with IO + IO ( p = .606). In conclusion, we confirm that sRCC are aggressive tumors with poor prognosis. IO‐based combinations improve survival outcomes of sRCC patients, regardless from the type of strategy (IO + IO versus IO + TKI) adopted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyAdultProtein Kinase InhibitorsPrognosisAged, 80 and over

Stichwörter der Autor:innen

ARON‐1 studyNCT05287464immune‐based combinationsimmunotherapyrenal cell carcinomasarcomatoid differentiationsurvival

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Medical Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
  • Department of Urology, University Hospital Bonn (UKB), Bonn, Germany.
  • Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.
  • Section of Innovation Biomedicine-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Oncology and Hematology Department, Hospital Sírio Libanê, Brasília, Brazil.
  • Oncology 3 Unit, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy.

ORCID-Profile: Chiara Ciccarese, Renate Pichler, Javier Molina-Cerrillo, Sebastiano Buti, Roberto Iacovelli

Zitieren

APA

Ciccarese, C., Büttner, T., Cerbone, L., Zampiva, I., Monteiro, F. S. M., Basso, U., Pichler, M., Vitale, M. G., Fiala, O., Roviello, G., Kopp, R. M., Carrozza, F., Pichler, R., Grillone, F., Calabuig, E. P., Zeppellini, A., Küronya, Z., Galli, L., Facchini, G., …, & Santoni, M. (2024). Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study). International Journal of Cancer. https://doi.org/10.1002/ijc.35141

Vancouver

Ciccarese C, Büttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, et al. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study). International Journal of Cancer. 2024. doi:10.1002/ijc.35141

BibTeX
@article{Ciccarese2024,
  author = {Ciccarese, Chiara and Büttner, Thomas and Cerbone, Linda and Zampiva, Ilaria and Monteiro, Fernando Sabino M and Basso, Umberto and Pichler, Martin and Vitale, Maria Giuseppa and Fiala, Ondrej and Roviello, Giandomenico and Kopp, Ray Manneh and Carrozza, Francesco and Pichler, Renate and Grillone, Francesco and Calabuig, Esther Pérez and Zeppellini, Annalisa and Küronya, Zsófia and Galli, Luca and Facchini, Gaetano and Sunela, Kaisa and Mosca, Alessandra and Molina-Cerrillo, Javier and Spinelli, Gian Paolo and Ansari, Jawaher and Scala, Alessandro and Mollica, Veronica and Grande, Enrique and Buti, Sebastiano and Kanesvaran, Ravindran and Zakopoulou, Roubini and Bamias, Aristotelis and Rizzo, Mimma and Massari, Francesco and Iacovelli, Roberto and Santoni, Matteo},
  title = {Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.35141}
}
Kostenlos starten →